BRD4 and cancer: OTX015, a thienotriazolodiazepine compound and a JQ1 analog, has been shown to inhibit binding of BRD2, BRD3, and BRD4 to acetylated histone 4 in a concentration-dependent manner, suggesting competitive inhibition, with IC50 values from 92-112nM (Kay Noel, American association for Cancer Research, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA, oral communication, Oct 22, 2013).